Plaque Research Today is a free monthly online journal that collates and summarizes the latest research about Plaque, including details on dentistry, brushing, oral hygiene, mouthwash.

The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain.

Tamura Y, Hamajima K, Matsui K, Yanoma S, Narita M, Tajima N, Xin KQ, Klinman D, Okuda K

Nichiiko Pharmaceutical, Co., Ltd, Toyama, Japan.

This work examines whether administering the F(ab' )2 fragment of an IgG1 monoclonal antibody (mAb) targeting the N-terminal 1-13 amino acids of the beta-amyloid peptide (Abeta mAb) reduces amyloid deposition in Alzheimer's disease (AD). The F(ab')2 fragment was injected intraperitoneally or intracranially into Tg2576 mice, a murine model of human AD. Both routes of administration significantly reduced Abeta plaque formation in the brain, as determined immunohistochemically and by monitoring levels of Abeta1-40 and Abeta1-42 peptide. Use of the F(ab')2 fragment significantly reduced phagocytic infiltration in the CNS when compared to intact mAb. Since IgG1 Abs do not fix complement, these findings suggest that effective in vivo clearance of amyloid deposits can be achieved without stimulation of FcR-reactive phagocytes or activation of the complement cascade.

Published 24 October 2005 in Neurobiol Dis, 20(2): 541-9.
Full-text of this article is available online (may require subscription).

© 2004-2008 Plaque Research Today. All Rights Reserved.